HCW Biologics Inc. 8-K

What Happened
HCW Biologics Inc. announced on May 27, 2026 (press release) that it elected on May 21, 2026 to terminate its exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206. The termination was made under Section 1(b) of a Suspension Letter Agreement the companies entered into on May 30, 2025, which allowed the Company to terminate the license during a 12‑month suspension period under specified conditions.

Key Details

• Termination date (election): May 21, 2026; press release furnished May 27, 2026 (Exhibit 99.1).
• Agreement referenced: Suspension Letter Agreement dated May 30, 2025, Section 1(b) (12‑month suspension clause).
• Assets affected: exclusive ex vivo license rights for two molecules — HCW9201 and HCW9206 — previously licensed to Wugen Inc.
• Filing type: Current Report on Form 8‑K; no financial terms or additional transaction details disclosed in this filing.

Why It Matters
For investors, this change removes Wugen’s exclusive ex vivo rights to HCW9201 and HCW9206 and signals HCW’s intent to change the partnership or licensing path for those assets under terms of the suspension agreement. The filing does not disclose financial considerations, a new partner, or impacts to development timelines or revenue. Monitor future filings and company communications for any announced licensing deals, financial terms, or development plans related to these molecules.